Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
6 pending office actions • 6 clients • 6 examiners • 5 art units • 0 of 6 (0%) have an AI response strategy ready
SMITH PATENT, LLC manages 442 career applications in the Biotechnology & Pharmaceuticals technology area. The firm has a resolved allowance rate pct of 86.42. Prosecution involves an avg office actions per allowance of 3.77.
There are 5 pending office actions currently active. The 86.42 resolved allowance rate pct for its 442 career applications reflects the firm's historical performance. An avg office actions per allowance of 3.77 provides a benchmark for the examination cycle in its primary technology area.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 2 (33%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHOI, PETER Y | 1 | 20.6% | +33.0% |
| HOLLAND, PAUL J | 1 | 57.5% | +64.6% |
| MUTCHLER, CHRISTOPHER JOHN | 1 | 55.9% | +20.4% |
| FAUST, AMBER KATHLEEN | 1 | 60.6% | +53.3% |
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18818331 | Composition Comprising an Alkyd Resin | CHOI, PETER Y | — |
| 18701828 | AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF | FAUST, AMBER KATHLEEN | — |
| 18044948 | CHIMERIC SENSOR PROTEIN AND METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18657444 | Methods, Systems, Devices and Components for the Treatment of Stroke in a Patient with Interferential Cranial Electrical Stimulation | MUTCHLER, CHRISTOPHER JOHN | 31d overdue |
| 18818331 | Composition Comprising an Alkyd Resin | CHOI, PETER Y | — |
| 18711814 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF PREGABALIN INTERMEDIATES | HOLLAND, PAUL J | — |
| 18701828 | AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF | FAUST, AMBER KATHLEEN | — |
| 18044948 | CHIMERIC SENSOR PROTEIN AND METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Munditia Technologies GmbH | 1 |
| Enzymaster (Ningbo) Bio-Engineering Co., Ltd. | 1 |
| Makous Research, LLC | 1 |
| Sinomab Bioscience Limited | 1 |
| Luye Pharma | 1 |
| Universitaet Leipzig | 1 |
| Art Unit | Apps |
|---|---|
| 1786 | 1 |
| 1656 | 1 |
| 3796 | 1 |
| 1615 | 1 |
| 1647 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18818331 | Composition Comprising an Alkyd Resin | Munditia Technologies GmbH | CHOI, PETER Y | 1786 | §102§103§112 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18711814 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF PREGABALIN INTERMEDIATES | Enzymaster (Ningbo) Bio-Engineering Co., Ltd. | HOLLAND, PAUL J | 1656 | §112 | Non-Final OA | — | Pending | May 20, 2024 |
| 18657444 | Methods, Systems, Devices and Components for the Treatment of Stroke in a Patient with Interferential Cranial Electrical Stimulation | Makous Research, LLC | MUTCHLER, CHRISTOPHER JOHN | 3796 | §103 | Final Rejection | 31d overdue | Pending | May 07, 2024 |
| 18701828 | AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF | Sinomab Bioscience Limited | FAUST, AMBER KATHLEEN | §102§103 | Non-Final OA | — | Pending | Apr 16, 2024 | |
| 17794886 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING THE INGREDIENT ROTIGOTINE AND AT LEAST ONE NON-AMINE-RESISTANT SILICONE ADHESIVE | Luye Pharma Switzerland AG | MERCIER, MELISSA S | 1615 | §112 | Final Rejection | 58d overdue | Pending | Mar 29, 2023 |
| 18044948 | CHIMERIC SENSOR PROTEIN AND METHODS OF USE THEREOF | Universitaet Leipzig | METCALF, MATTHEW CURRAN | 1647 | §103§112 | Non-Final OA | — | Pending | Mar 10, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial